General Information:

Id: 6,509 (click here to show other Interactions for entry)
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Homo sapiens
Reference: Bandyopadhyay GK et al.(2006) Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects Diabetes 55: 2277-2285 [PMID: 16873691]

Interaction Information:

Comment In type 2 diabetic subjects, basal fatty acid oxidation rates were significantly reduced with no significant further effect of insulin. After rosiglitazone treatment, basal fatty acid oxidation rates were partially restored to normal, and the insulin effect to lower fatty acid oxidation was restored.
Formal Description
Interaction-ID: 61856

drug/chemical compound


increases_activity of

in muscle
Drugbank entries Show/Hide entries for Rosiglitazone